Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

NeuroBo Pharmaceuticals, Inc. NRBO NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
49/100
2/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

NeuroBo Pharmaceuticals, Inc. (NRBO) — Analyst outlook / Analyst consensus target is. Based on 2 analyst ratings, the consensus is bullish — 2 Buy.

NRBO Analyst Ratings

Buy
2
Ratings
2 Buy
Based on 2 analysts giving stock ratings to NeuroBo Pharmaceuticals, Inc. in the past 3 months
Rating breakdown
Buy
2 100%
100%
Buy
2 analysts
0%
Hold
0 analysts
0%
Sell
0 analysts

People Also View

ATNF
ATNF
180 Life Sciences Corp.
$7.04
-7.49%
 ZURA
ZURA
Zura Bio Limited
$5.72
+0.70%
 ALLR
ALLR
Allarity Therapeutics, Inc.
$1.19
-0.76%
 PHIO
PHIO
Phio Pharmaceuticals Corp.
$1.29
+4.03%
 KPRX
KPRX
Kiora Pharmaceuticals, Inc.
$2.44
-0.33%
 SONN
SONN
Sonnet BioTherapeutics Holdings, Inc.
$1.26
-59.35%
 REVB
REVB
Revelation Biosciences, Inc.
$1.20
+0.84%
 HILS
HILS
Hillstream BioPharma, Inc.
$0.24
+5.66%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message